Merck's LIPFENDRA Becomes First Oral PCSK9 Inhibitor, Ending a Decade of Injectable Frustration

The FDA approved LIPFENDRA (enlicitide) on July 16, 2026, the first and only once-daily oral PCSK9 inhibitor for reducing LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Merck (MRK) won a race it has been running for years.

The trial data

The approval is based on two Phase 3 trials from the CORALreef clinical program:

• CORALreef Lipids: 56% placebo-adjusted LDL-C reduction at week 24. Secondary endpoints showed 52% reduction in non-HDL cholesterol and 48% reduction in apolipoprotein B. Safety profile was similar to placebo.
• CORALreef HeFH: 59% LDL-C reduction at week 24 in patients with the genetic form of high cholesterol.

LIPFENDRA is a 20 mg once-daily tablet. It is a novel macrocyclic peptide that binds to PCSK9 and blocks its interaction with LDL receptors. The oral formulation is the breakthrough here. Making a peptide survive the digestive tract and reach its target intact is a formulation problem that took years to solve.

Why injectable PCSK9 inhibitors disappointed

PCSK9 inhibitors have been a biotech cautionary tale. Amgen’s Repatha and the Regeneron/Sanofi Praluent launched as injectables with $14,000-plus annual price tags. The science was excellent. The sales were not.

The problems were practical. Injectables are harder to prescribe than pills. Payers imposed prior authorization requirements that discouraged physicians from prescribing them. Patients disliked self-injection for a condition they could not feel. The result: a market that analysts once projected at $10 billion plus stayed stuck under $1 billion.

A pill changes that calculus. Pills are easier to prescribe, easier to take, and face less reimbursement friction. RBC Capital noted LIPFENDRA has “the cleanest label in the PCSK9 class” with zero contraindications or hypersensitivity warnings. That clean label should help with payer negotiations.

For context on how FDA approval decisions work, see our coverage of Vertex’s suzetrigine PDUFA.

How PCSK9 inhibitors work

PCSK9 is a protein that breaks down LDL receptors in the liver. Fewer LDL receptors means more LDL cholesterol stays in the blood. A PCSK9 inhibitor blocks that protein, preserving LDL receptors so the liver can clear more LDL from circulation. The mechanism is well established. The problem was always delivery and cost.

What this means for Merck

Merck needs diversification beyond Keytruda, which faces a patent cliff in 2028. LIPFENDRA gives Merck a cardiovascular franchise entry point. The PCSK9 market has been underserved for a decade, and an oral inhibitor could finally unlock it.

Merck beat AstraZeneca to the oral PCSK9 milestone. Being first matters in a market where prescriber habits and payer formularies are sticky.

What to watch next

1. Pricing and access: Merck has not disclosed the list price. If LIPFENDRA prices near statin levels, uptake could be rapid. If it prices near injectable PCSK9 levels, it faces the same payer resistance.
2. Prescription data: Early NDC data in Q4 2026 will show whether cardiologists adopt the pill quickly.
3. Outcomes trial: LDL-C reduction is a surrogate endpoint. A cardiovascular outcomes trial would strengthen the case for broader reimbursement.

Merck closed at $130.48 on July 22. The stock is up 19.75% year to date, with LIPFENDRA adding to the momentum alongside other pipeline catalysts.

Source: Merck press release | TCTMD

What It Means for the Trade

LIPFENDRA is the closest thing to a category killer the lipid market has produced in a decade, and the trade runs on pricing. The injectable PCSK9 market stalled under $1 billion against $10 billion-plus projections because payers built prior-auth walls around $14,000-a-year injectables; a once-daily pill with zero contraindications or hypersensitivity warnings — RBC’s “cleanest label in the class” — attacks the reimbursement friction directly. Every pricing scenario is on the table and Merck has not disclosed the list price: near-statin pricing means rapid uptake and a genuine diversification pillar ahead of Keytruda’s 2028 cliff; near-injectable pricing recreates the payer fight and squanders the format advantage. The dated catalysts are Q4 2026 NDC data (cardiologist adoption speed) and the cardiovascular outcomes trial, which converts LDL-lowering into the mortality evidence payers ultimately price against. Being first to oral matters: prescriber habits and formulary tiers are sticky, and AstraZeneca’s oral candidate now enters as the challenger rather than the standard.

Mechanism and Market Context

Enlicitide is a macrocyclic peptide — a ring-shaped molecule engineered to survive oral bioavailability, a formulation feat peptides rarely achieve — that binds PCSK9 in the gut and circulation, blocking its destruction of LDL receptors so the liver keeps clearing LDL from blood. The CORALreef program’s numbers (56% placebo-adjusted LDL-C reduction in hypercholesterolemia, 59% in HeFH, with 52% non-HDL and 48% apoB reductions) land squarely in injectable-PCSK9 territory, meaning the oral format sacrifices nothing measurable in potency. The market context is the entire story: PCSK9 inhibition is proven biology with a decade of outcomes data behind the class; the unmet need was never efficacy, it was the delivery-and-access chain. An estimated patient population spanning statin-intolerant, inadequately controlled, and familial hypercholesterolemia segments gives LIPFENDRA a deeper funnel than the injectables ever reached.

Risks and What Could Go Wrong

1. Pricing is the binary: a premium price revives the prior-authorization dynamic that buried Repatha and Praluent.
2. LDL-C reduction is a surrogate; without its own completed outcomes trial, payers may tier the pill below generic statin-ezetimibe combinations.
3. AstraZeneca and other oral followers can compress the first-mover window quickly if Merck’s launch stumbles.
4. Novel oral peptide formulations can surface real-world tolerability or absorption issues that registration trials under-capture.